亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Projected Health and Economic Burden of Comorbid Gout and Chronic Kidney Disease in a Virtual US Population: A Microsimulation Study

痛风 医学 共病 肾脏疾病 人口 疾病负担 医疗保健 内科学 环境卫生 重症监护医学 物理疗法 经济 经济增长
作者
Joshua Card-Gowers,Lise Retat,Ada Kumar,Brad A. Marder,Lissa Padnick‐Silver,Brian D. LaMoreaux,Laura Webber
出处
期刊:Rheumatology and therapy [Adis, Springer Healthcare]
卷期号:11 (4): 913-926 被引量:5
标识
DOI:10.1007/s40744-024-00681-2
摘要

INTRODUCTION: Gout, a common comorbidity of chronic kidney disease (CKD), is associated with high morbidity and healthcare utilization. However, a large proportion of gout remains undermanaged or untreated which may lead to worse patient outcomes and greater healthcare costs. This study estimates the present and future health and economic burden of controlled and uncontrolled gout in a virtual United States (US) CKD population. METHODS: A validated microsimulation model was used to project the burden of gout in patients with CKD in the USA through 2035. Databases were utilized to build a virtual CKD population of "individuals" with controlled or uncontrolled gout. Modelling assumptions were made on the basis of the literature, which was sparse in some cases. Health and economic outcomes with the current care (baseline) scenario were evaluated, along with potential benefits of urate-lowering intervention scenarios. RESULTS: The prevalence of comorbid gout and CKD in the USA was projected to increase by 29%, from 7.9 million in 2023 to 9.6 million in 2035 in the baseline scenario. Gout flares, tophi, and comorbidity development were also projected to increase markedly through 2035, with the economic burden of gout in the CKD population subsequently increasing from $38.9 billion in 2023 to $47.3 billion in 2035. An increased use of oral urate-lowering therapies in undermanaged patients, and pegloticase use in patients refractory to oral urate-lowering therapies were also project to result in 744,000 and 353,000 fewer uncontrolled gout cases, respectively, by 2035. Marked reductions in complications and costs ensued. CONCLUSIONS: This study projected a substantial increase in comorbid gout and CKD. However, improved use of urate-lowering interventions could mitigate this growth and reduce the health and economic burdens of gout.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
3秒前
王艳发布了新的文献求助10
9秒前
zsp完成签到,获得积分10
9秒前
感存算完成签到,获得积分10
12秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
13秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
13秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
14秒前
14秒前
FashionBoy的应助被科研通管家采纳,获得10
14秒前
SciGPT的应助被英俊大树采纳,获得10
14秒前
微笑南烟发布了新的文献求助10
19秒前
23秒前
幸福的沛萍完成签到,获得积分10
24秒前
微笑南烟完成签到,获得积分10
29秒前
ppp发布了新的文献求助10
33秒前
曲聋五完成签到 ,获得积分0
39秒前
初景的应助被是磊啊采纳,获得20
39秒前
Ballyhooed完成签到,获得积分10
41秒前
42秒前
嘻嘻哈哈的应助被Minnie采纳,获得10
43秒前
康子浩发布了新的文献求助10
45秒前
英俊大树发布了新的文献求助10
48秒前
暖暖发布了新的文献求助10
48秒前
50秒前
52秒前
52秒前
虚心的迎彤完成签到,获得积分10
52秒前
54秒前
雪山大地发布了新的文献求助10
55秒前
Zhou完成签到 ,获得积分10
55秒前
英俊大树完成签到,获得积分10
55秒前
和谐以冬发布了新的文献求助10
56秒前
研友_VZG7GZ的应助被暖暖采纳,获得10
57秒前
CodeCraft的应助被王艳采纳,获得10
1分钟前
histamin完成签到,获得积分10
1分钟前
1分钟前
1分钟前
Collice发布了新的文献求助30
1分钟前
杏仁核发布了新的文献求助10
1分钟前
充电宝的应助被康子浩采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165939
求助须知:如何正确求助?哪些是违规求助? 9559318
关于积分的说明 21749898
捐赠科研通 7756692
什么是DOI,文献DOI怎么找? 3429083
关于科研通互助平台的介绍 2553385
邀请新用户注册赠送积分活动 2473623